1. Home
  2. RNG vs CNTA Comparison

RNG vs CNTA Comparison

Compare RNG & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RingCentral Inc.

RNG

RingCentral Inc.

HOLD

Current Price

$39.67

Market Cap

3.5B

Sector

Technology

ML Signal

HOLD

Logo Centessa Pharmaceuticals plc

CNTA

Centessa Pharmaceuticals plc

HOLD

Current Price

$39.50

Market Cap

6.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNG
CNTA
Founded
1999
2020
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
6.1B
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
RNG
CNTA
Price
$39.67
$39.50
Analyst Decision
Hold
Buy
Analyst Count
14
9
Target Price
$33.58
$43.17
AVG Volume (30 Days)
1.4M
4.9M
Earning Date
05-07-2026
05-13-2026
Dividend Yield
0.74%
N/A
EPS Growth
176.19
29.13
EPS
0.48
N/A
Revenue
$2,515,142,000.00
$15,000,000.00
Revenue This Year
$5.56
N/A
Revenue Next Year
$4.56
N/A
P/E Ratio
$84.60
N/A
Revenue Growth
4.78
N/A
52 Week Low
$23.59
$10.95
52 Week High
$43.83
$40.26

Technical Indicators

Market Signals
Indicator
RNG
CNTA
Relative Strength Index (RSI) 54.09 73.71
Support Level $25.56 $39.16
Resistance Level $43.13 $40.26
Average True Range (ATR) 2.24 0.22
MACD 0.07 -0.45
Stochastic Oscillator 61.55 52.34

Price Performance

Historical Comparison
RNG
CNTA

About RNG RingCentral Inc.

RingCentral is a unified communications as a service, or UCaaS, provider. Its software helps users communicate and collaborate via voice, video, and messaging across all device types and all from one platform. RingCentral helps customers modernize and move from legacy on-premises systems to modern, cloud-based systems. Beyond its core RingCentral MVP solution, RingCentral also offers a cloud-based contact center solution, a stand-alone video meetings solution, and webinars.

About CNTA Centessa Pharmaceuticals plc

Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.

Share on Social Networks: